---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-048469"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2026-07-16T20:25:02+00:00"
generated_at: "2026-07-16T20:26:05.562467+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Arcutis appoints Christopher Peetz to Board of Directors

## Summary
- Christopher Peetz appointed as Class III director effective July 15, 2026; term expires at 2029 annual meeting.
- Peetz is co-founder and CEO of Mirum Pharmaceuticals; brings biopharma leadership and M&A experience.
- Received initial option for 21,486 shares; eligible for prorated annual equity (~$350K) and $50K cash retainer.
- Board determined Peetz qualifies as independent under SEC and Nasdaq rules; no committee assignment yet.
- Appointment expands board from nine to ten members; no family or material transaction relationships disclosed.

## SEC filing metadata
- accession: 0001628280-26-048469
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2026-07-16T20:25:02+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828026048469/0001628280-26-048469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828026048469/arqt-20260715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-048469
- JSON: https://secwatch.observer/filing/0001628280-26-048469.json
- Plain text: https://secwatch.observer/filing/0001628280-26-048469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.